Inside BSP Pharmaceuticals’ 2026 ISPE Facility of the Year Awards (FOYA) Supply Chain Category Award-Winning Project
As antibody-drug conjugates (ADCs) continue to transform cancer treatment, manufacturers face increasing pressure to deliver these highly complex therapies faster, more safely, and with greater reliability. Yet one of the industry's most persistent challenges remains the fragmented supply chain traditionally required to produce ADCs.
BSP Pharmaceuticals’ integrated ADC manufacturing facility in Latina, Italy, offers a compelling solution. Recognized as a 2026 ISPE FOYA Category Winner in Supply Chain, the project reimagines how ADCs are manufactured by bringing drug substance (DS) conjugation and drug product (DP) fill-finish operations together under a single quality system. The result is a more resilient, efficient, and patient-focused manufacturing model that reduces risk while accelerating delivery of life-saving oncology treatments.
Solving a Critical ADC Manufacturing Bottleneck
Founded in 2006, BSP Pharmaceuticals is an Italian contract development and manufacturing organization (CDMO) specializing in oncology, cytotoxic, and immunotherapy products. The company currently manufactures 13 of the 19 ADCs approved for the commercial market and provides service support for more than 100 bioconjugated clinical programs.
Historically, ADC manufacturing has depended on multiple facilities, often spread across different regions or countries. Monoclonal antibodies may originate at one site, linker-payload components at another, conjugation occurs elsewhere, and fill-finish operations take place at yet another location. Each transfer introduces complexity, increases cold-chain risks, and creates opportunities for delays that can ultimately impact patient access. BSP’s Latina facility was designed to eliminate those challenges.
By co-locating conjugation and fill-finish operations within a single site, BSP has created a fully integrated manufacturing environment capable of supporting ADC production from investigational new drug (IND) development through commercial supply. This approach significantly reduces inter-site transfers, streamlines logistics, and strengthens supply chain resilience.
“Inter-site transfers of highly potent, cytotoxic intermediates introduce exposure risk, cold chain challenges, and the potential for quality deviations during transit,” said Aldo Braca, Chief Executive Officer and President of BSP Pharmaceuticals. “By housing both steps at Latina, end-to-end integration compresses the overall manufacturing cycle, strengthens batch traceability, and gives us a unified point of accountability for the entire ADC production process.”
Creating a Fully Integrated Supply Chain
The Latina facility represents a significant departure from conventional ADC manufacturing models. Rather than moving sensitive materials between multiple sites, the facility receives all critical components and produces fully packaged drug product through a unified manufacturing process.
This integration delivers several important advantages:
- Reduced transportation and cold-chain risks
- Improved traceability throughout the manufacturing lifecycle
- Faster manufacturing and batch release timelines
- Greater operational visibility
- Enhanced supply chain reliability
The site also includes on-site storage capable of maintaining temperatures as low as -80°C, eliminating the need to transport temperature-sensitive intermediates between facilities. Monoclonal antibodies, cytotoxin-linkers, and ADC intermediates remain protected within a controlled environment, reducing handling complexity and minimizing opportunities for product degradation. For patients awaiting innovative oncology treatments, those efficiencies can translate into faster and more predictable access to therapy.
One Quality System from Drug Substance to Drug Product
A defining feature of the project is its unified quality management system (QMS), which spans both DS and DP manufacturing operations. In traditional manufacturing environments, separate facilities often operate under different procedures, documentation systems, and quality oversight structures. Coordinating across multiple quality organizations can increase complexity and slow issue resolution.
At BSP’s Latina site, quality oversight functions as a continuous process across the entire manufacturing journey. “Co-locating drug substance and drug product operations creates a continuous quality oversight loop that simply isn't achievable when the two steps are separated,” Braca said. “Quality control teams can monitor critical quality attributes, including conjugation efficiency, drug-to-antibody ratio, and aggregation levels, and immediately apply those insights to the downstream fill-finish process without the delays inherent in inter-site communication.”
Because quality teams operate within a shared framework, any out-of-trend observations identified during DS production can be reviewed and addressed before material advances downstream. Shared analytical resources also eliminate unnecessary testing transfers and reduce variability that can occur when work moves between organizations.
The outcome is greater consistency, stronger compliance, improved traceability, and faster batch disposition decisions. “Ultimately, the proximity of drug substance and drug product operations fosters a culture of integrated quality ownership, where every team member understands how their work connects to the final product delivered to patients,” Braca said.
Streamlining Regulatory Readiness
Integrated manufacturing also provides meaningful regulatory advantages. When DS and DP manufacturing occur at separate facilities, regulatory authorities may need to inspect multiple sites independently. Each location requires its own manufacturing authorizations, procedures, documentation, and quality systems. Coordinating those activities can increase complexity and lengthen timelines.
The Latina site allows regulators to evaluate the entire production process in a single location. “At Latina, inspectors can assess the full manufacturing journey in a single visit, from conjugation through final fill-finish,” Braca said. “There is one integrated quality system, one unified set of batch records, and one accountable manufacturing team.”
This consolidated approach simplifies inspections, accelerates responses to regulatory questions, and reduces the likelihood of inconsistencies between manufacturing sites. It also streamlines chemistry, manufacturing, and controls documentation and facilitates post-approval change management. For therapies pursuing accelerated development pathways, those efficiencies can help support faster commercial readiness while maintaining robust compliance standards.
Safety Built into the Design
ADC manufacturing requires handling some of the pharmaceutical industry's most potent compounds. Managing these materials safely is essential for protecting workers, product quality, and the surrounding environment.
The compounds handled at BSP’s Latina facility include cytotoxic payloads with occupational exposure limits below 10 nanograms per cubic meter. Every transportation event introduces additional safety, packaging, and emergency-response considerations. By consolidating operations at one location, BSP significantly reduces the number of transfer points where exposure incidents could occur.
“The design of the Latina plant confines the handling of highly potent active pharmaceutical ingredient-conjugated intermediates to one containment-engineered environment with a highly trained workforce operating under a unified safety management system,” Braca said.
The facility employs a single containment strategy, a unified spill-response protocol, and engineering controls specifically optimized for ADC manufacturing activities.
The project's safety performance during construction further demonstrates this commitment. BSP recorded a lost-time injury rate of only 0.14 across approximately 1.4 million work hours and conducted more than 900 safety toolbox talks during project execution.
Accelerating Time to Market for Patients
Perhaps the most significant benefit of the Latina facility is its ability to reduce manufacturing cycle times. For oncology therapies, delays associated with inter-site shipping, batch handoffs, duplicated testing, and disconnected release schedules can have a direct impact on when therapies become available to patients.
Through supply chain integration, BSP has removed many of those inefficiencies. “Thanks to Latina's integrated supply chain, we have eliminated many of these points of inefficiency,” Braca said. “Batch release decisions are made with full visibility across both drug substance and drug product, without waiting for material to arrive from a remote site. This allows for a faster, more agile response to demand fluctuations or clinical trial schedule changes.”
For innovative cancer therapies, where urgency often matters, reducing cycle time while maintaining quality can create meaningful benefits for both patients and sponsors. By demonstrating that complex ADC manufacturing can be consolidated, streamlined, and safely scaled, BSP Pharmaceuticals has established a new model for resilient pharmaceutical supply chains.
“The expansion of the Latina site establishes a new standard for supply chain resilience and rapid product delivery,” Braca said. “For patients and partners alike, it means a more reliable, predictable supply of complex, life-saving therapies.”
